ISTH 2022 Congress
Coagulation and Natural Anticoagulants
Theme Navigation
-
Abstract Number: OC 44.3
A new mouse model of impaired fibrin α-chain crosslinking shows increased venous thrombembolism
-
Abstract Number: OC 65.3
A Phase 2 Trial Evaluating the Safety and Antithrombotic Efficacy of AB002, a First-in-class Protein C Activator in End-stage Renal Disease Patients on Heparin-free Hemodialysis
-
Abstract Number: PB0552
A Probable Therapeutic for a Child with Inherited Protein S Deficiency
-
Abstract Number: VPB0572
A study of the stability of fibrinogen and FXIII levels and microbial integrity of pooled cyroprecipitate stored at 1-6°C and 20-24°C for up to 120 hours
-
Abstract Number: OC 36.4
A Tethered Artificial Protease Reveals the Location of Key Regulatory Motifs in Factor V
-
Abstract Number: PB0548
Abelacimab, a Factor XI/XIa Antibody Inhibits Clotting in Hemodialysis Circuits Ex Vivo
-
Abstract Number: OC 44.1
Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome
-
Abstract Number: OC 03.5
An Integrative Biology Approach to Model the Role of the Feedback Activation of FXI by Thrombin in the Tissue Factor Pathway
-
Abstract Number: OC 36.3
Analysis of TFPI-protein S anticoagulant function in vivo.
-
Abstract Number: OC 65.2
Andexanet alfa is associated with a significant reduction in in-hospital mortality compared to 4F-PCC in a real-world analysis
-
Abstract Number: LB 01.5
Antiplatelet effects of inhibiting coagulation factor XI in a non-human primate model of atherosclerosis
-
Abstract Number: OC 67.1
Antithrombin deficiency and altered heparin responsiveness during veno-arterial extracorporeal life support: a prospective study
-
Abstract Number: PB0547
Antithrombin deficiency is associated with more compact plasma fibrin clot structure and impaired susceptibility to fibrinolysis
-
Abstract Number: PB1016
Argatroban Monitoring in Critically Ill Patients and correlation with Thrombin Generation
-
Abstract Number: VPB1019
Assessing the reversal efficacy of prothrombin complex concentrate (PCC) and andexanet alfa in rivaroxaban-anticoagulated blood: Ex vivo study
-
Abstract Number: VPB0570
Assessment of Impact of Metabolites of Edoxaban and Dabigatran on Fibrin and Thrombin Generation Assays
-
Abstract Number: PB1015
Assessment of Quantra Analyzer on life-threating bleeding under oral anticoagulants agents: a pilot study
-
Abstract Number: PB0542
Bio-equivalence of Potency adjusted approved heparin solutions compared to a newly developed heparin solution.
- 1
- 2
- 3
- …
- 7
- Next Page »